Novo Nordisk Receives BLA Approval for Esperoct (turoctocog alfa pegol, N8-GP) for Patients with Haemophilia A

 Novo Nordisk Receives BLA Approval for Esperoct (turoctocog alfa pegol, N8-GP) for Patients with Haemophilia A

Novo Nordisk Receives BLA Approval for Esperoct (turoctocog alfa pegol, N8-GP) for Patients with Haemophilia A

Shots:

  • The BLA approval is based on the trial assessing Esperoct (turoctocog alfa pegol, N8-GP) in 270 patients with previously treated people (PTPs) with severe haemophilia A
  • The study resulted in maintanince of low median ABR of 1.18, efficacious in treatment & control of bleeding episodes, perioperative management and was well tolerated with no safety concerns observed
  • Esperoct (turoctocog alfa pegol, N8-GP) is an extended half-life factor VIII molecule indicated as a replacement therapy in people with haemophilia A and will be marketed in US in 2020

Click here to read full press release/ article| Ref: Novo Nordisk | Image: Azernews

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post